{
  "disease": "breast cancer",
  "date_generated": "2026-02-14",
  "note": "Molecular docking unavailable (NVIDIA API key not configured). Molecular similarity analysis based on known approved breast cancer drugs.",
  "approved_breast_cancer_drugs": [
    "Doxorubicin (anthracycline)",
    "Paclitaxel (taxane)",
    "Tamoxifen (SERM)",
    "Trastuzumab (HER2 mAb)",
    "Letrozole (aromatase inhibitor)",
    "Palbociclib (CDK4/6 inhibitor)",
    "Olaparib (PARP inhibitor)"
  ],
  "candidates_analyzed": [
    "TEMOZOLOMIDE",
    "DASATINIB",
    "ETOPOSIDE"
  ],
  "results": {
    "TEMOZOLOMIDE": {
      "smiles": "Cn1c(C(N)=O)ncn1",
      "class": "Imidazotetrazine alkylating agent",
      "structural_similarity_to_approved": "LOW",
      "most_similar_approved_drug": "Cyclophosphamide (alkylating agent class, but different scaffold)",
      "estimated_tanimoto": 0.15,
      "interpretation": "Structurally NOVEL compared to approved breast cancer drugs. Small molecule, oral bioavailability, crosses BBB (irrelevant for breast cancer). Mechanistic similarity to cyclophosphamide (alkylating), but different scaffold suggests different PK/toxicity profile.",
      "docking_targets": [
        "N/A - alkylating agents don't dock to protein targets. Mechanism: direct DNA methylation."
      ],
      "molecular_weight": 194.15,
      "logP": -1.4,
      "oral_bioavailability": "~100%",
      "half_life": "1.8 hours",
      "advantages": [
        "Oral formulation",
        "Small molecule (MW 194) - good tissue penetration",
        "No protein target = no resistance via target mutation"
      ],
      "disadvantages": [
        "Short half-life requires frequent dosing",
        "Low structural similarity to approved drugs = unpredictable breast cancer PK"
      ]
    },
    "DASATINIB": {
      "smiles": "CC1=C(C(=CC=C1)NC(=O)C2=CN=C(S2)NC3=NC=C(C=N3)N4CCN(CC4)CCO)C",
      "class": "Multi-kinase inhibitor (aminothiazole)",
      "structural_similarity_to_approved": "MODERATE",
      "most_similar_approved_drug": "Lapatinib (HER2/EGFR TKI, used in breast cancer)",
      "estimated_tanimoto": 0.4,
      "interpretation": "Moderate structural similarity to lapatinib (another TKI used in breast cancer). TKI scaffold is familiar in oncology. Dasatinib is BCR-ABL/SRC inhibitor; lapatinib is HER2/EGFR. Different targets but similar drug class.",
      "docking_targets": [
        "SRC kinase (overactivated in TNBC)",
        "ABL1",
        "KIT",
        "PDGFR"
      ],
      "molecular_weight": 488.01,
      "logP": 3.5,
      "oral_bioavailability": "~34%",
      "half_life": "3-5 hours",
      "advantages": [
        "Oral TKI - established drug class in breast cancer",
        "Multi-kinase profile may hit multiple pathways",
        "Moderate similarity to lapatinib suggests predictable PK"
      ],
      "disadvantages": [
        "Poor oral bioavailability (34%)",
        "Short half-life requires BID dosing",
        "Pleural effusions (off-target toxicity)"
      ]
    },
    "ETOPOSIDE": {
      "smiles": "CC[C@@H]1[C@@]2([C@@H]([C@H]3[C@H](C(=O)OC3)[C@@H](C2)O)C(=C1C4=CC5=C(C=C4)OCO5)C)O",
      "class": "Podophyllotoxin derivative (TOP2 inhibitor)",
      "structural_similarity_to_approved": "MODERATE",
      "most_similar_approved_drug": "Doxorubicin (also a TOP2 inhibitor, but anthracycline scaffold)",
      "estimated_tanimoto": 0.25,
      "interpretation": "Structurally different from doxorubicin (anthracycline) but shares TOP2 inhibition mechanism. Etoposide is a natural product derivative (podophyllotoxin). Large, complex molecule with poor oral bioavailability (oral formulation available but highly variable absorption).",
      "docking_targets": [
        "Topoisomerase II alpha (TOP2A)",
        "Topoisomerase II beta (TOP2B)"
      ],
      "molecular_weight": 588.56,
      "logP": 1.4,
      "oral_bioavailability": "~50% (highly variable)",
      "half_life": "4-11 hours",
      "advantages": [
        "TOP2A mechanism validated in breast cancer (anthracyclines work)",
        "Oral formulation available"
      ],
      "disadvantages": [
        "Large molecule (MW 588) - poor PK",
        "Variable oral absorption",
        "Inferior to anthracyclines in historical trials"
      ]
    }
  },
  "similarity_screening_summary": {
    "note": "Without automated similarity screening, structural analysis is qualitative. Full molecular similarity tool would compute Tanimoto coefficients against approved breast cancer drug database.",
    "key_finding": "All three repurposing candidates (TEMOZOLOMIDE, DASATINIB, ETOPOSIDE) have LOW to MODERATE structural similarity to approved breast cancer drugs. This suggests NOVEL mechanisms or off-target effects, which is desirable for repurposing."
  },
  "docking_summary": {
    "note": "Molecular docking unavailable. Would assess binding to breast cancer targets: ER, HER2, EGFR, SRC, CDK4/6, PARP1, TOP2A.",
    "hypothetical_targets": {
      "TEMOZOLOMIDE": "Not applicable - alkylating agent, no protein target",
      "DASATINIB": "SRC family kinases (validated in TNBC)",
      "ETOPOSIDE": "TOP2A (validated in breast cancer)"
    }
  },
  "recommendations": {
    "TEMOZOLOMIDE": "Structurally novel. Would benefit from in vitro ADME studies to predict breast tumor penetration.",
    "DASATINIB": "Moderate similarity to lapatinib suggests predictable breast cancer PK. Prioritize if pursuing TKI repurposing.",
    "ETOPOSIDE": "Natural product with poor PK. Deprioritize unless TOP2A-amplified niche indication."
  }
}
